As a company dedicated to delivering the highest standards of service for specialised pharmaceutical storage & distribution solutions, we are proud to be able to announce that BS3’s strong growth continues. With our newest state-of-the-art Schedule 8/9 pharmaceutical storage vault commissioned mid 2023 already at 75% capacity, we are thrilled to unveil that a third vault is now currently under construction.
In a competitive pharmaceutical storage market, differentiation is essential for success. At BS3 Pharmaceutical Storage & Distribution Specialists, we set ourselves apart by offering customized solutions, prioritizing long-term partnerships, upholding ethical business practices, and delivering unmatched value. Our focus is on meeting our clients' unique needs and exceeding their expectations rather than engaging in ruthless competition or catering to the highest bidder. By choosing BS3 Boutique Storage Specialists, clients can rest assured that they are partnering with a reliable and trustworthy provider that has their best interests at heart
Clinical trials are an important part of the drug development process, requiring careful planning and execution to ensure the safety and efficacy of the drugs being tested. Good Distribution Practices (GDP) is an essential part of this, guaranteeing quality standards and guidelines govern the storage, transportation, and distribution of pharmaceutical products.
We are thrilled to share that due to continued strong growth in demand, BS3 is embarking on the next phase of expansion and proudly announce the launch of our next state-of-the-art pharmaceutical Schedule 8/9 vault. This new vault not only expands our storage capabilities but also enhances the security and protection of your valuable assets. As a company dedicated to delivering the highest standards of service, we recognize the need for specialised storage solutions. Our Pharmaceutical Schedule 8/9 Vault has been designed with cutting-edge security features and advanced technology.
3rd February 2023, the Therapeutic Goods Administration (TGA) announced that from the 1st July 2023, medical use of MDMA and Psilocybin will be rescheduled from Schedule 9 (prohibited substances) to Schedule 8 (controlled medicines) of the Poisons Standard. Which will enable authorised psychiatrists to prescribe these substances for treatment-resistant depression and treatment resistant post-traumatic stress disorder.